Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.
about
Crystal Structure of tert -Butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in Complex with HIV-1 Reverse Transcriptase (RT) Redefines the Elastic Limits of the Non-nucleoside Inhibitor-Binding PocketUnique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitorUnique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolideIn vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidineSJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapySusceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitorsResistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives)Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strainsResistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidinesSelective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile anStructure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilidePreclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication(Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIdentification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activitySRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virusS-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase.Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT.Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.Antiviral therapy for human immunodeficiency virus infectionsInhibition of human immunodeficiency virus by a new class of pyridine oxide derivatives.Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy.Biochemical mechanism of HIV-1 resistance to rilpivirine.Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors.
P2860
Q27667348-E19114AF-2FE5-468A-B017-1D387D249A2FQ27735940-40A9DC73-154F-485E-8FC6-4D23CDC93842Q28343461-7B6740C1-C789-4C36-9713-E439A4DCA4FBQ28344355-383866DB-1859-49B6-B9C2-E2432DC31A95Q28346130-5E348903-1377-4295-AF39-5333FFEFA08EQ28367526-B75EB898-C7F4-4367-8040-AEF48AB1785EQ28367590-19A031BA-435F-40C6-A804-7E3048659E6CQ28367603-57587790-DC82-4779-A7F2-36577A908FACQ28367704-D4C23AC5-71D7-4223-9CA0-B331AD7A8135Q28367707-DB54C1AE-2FF3-445C-B77D-C689A8C707C5Q28368381-18BA5A22-E732-4141-9042-5D98B9D010BCQ28378760-A1BD237B-7CF1-40CD-BCD7-4AB342D2769DQ28378796-5277BE74-C368-482E-B8B5-E0FC8CE5A08CQ28378825-E4BBCCDA-006C-4659-8814-14BE86D72353Q28378859-1FE597F1-C954-4C1E-A4D3-298ED3A37760Q28379002-93F9508C-8E5C-4C80-AFB7-1AA116EBFAC9Q28379406-894D3318-A17B-4D71-B12F-AE6D946F43C3Q28379459-1712061E-93AA-4B9E-A43D-4DFA4BD51EBEQ28379544-6D170C37-E961-482A-AC9C-DC0E41CDA7A1Q33757596-5943B029-BF4F-4DB5-BC08-CB95633FD9BEQ33827080-25423D30-96B6-4464-B06C-9A6A04559FBAQ34181367-D3D55449-C19C-4FD6-A394-843670953BE2Q35125592-F0139436-A7FD-4E3B-BC5D-5F846DA45D9CQ35366050-C7CDF621-CC58-4FB4-A1D8-DBC1EA810DBDQ35685039-5484B611-1AAD-4B1E-B072-018BE5A880C6Q35828466-651ED100-A3A9-4A93-8F64-E50BF452C774Q36368294-639E8706-AAFA-4DFD-9E1F-E7A6F31AD888Q36689086-21FC206C-7FA9-4380-AF70-167CA8235779
P2860
Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Treatment of human immunodefic ...... ment with single-drug therapy.
@ast
Treatment of human immunodefic ...... ment with single-drug therapy.
@en
type
label
Treatment of human immunodefic ...... ment with single-drug therapy.
@ast
Treatment of human immunodefic ...... ment with single-drug therapy.
@en
prefLabel
Treatment of human immunodefic ...... ment with single-drug therapy.
@ast
Treatment of human immunodefic ...... ment with single-drug therapy.
@en
P2093
P2860
P1433
P1476
Treatment of human immunodefic ...... tment with single-drug therapy
@en
P2093
Balzarini J
Camarasa MJ
De Clercq E
Pérez-Pérez MJ
Tarpley WG
P2860
P304
P407
P577
1993-09-01T00:00:00Z